

New Behçet's Management Guidelines Issued

BY DENISE NAPOLI
Assistant Editor

Nine new recommendations for the management of Behçet's disease have been issued by the European League Against Rheumatism, based on a literature review from 1966 through 2006.

Guidelines relating to the oral, dermatologic, ocular, and joint manifestations of Behçet's disease (BD) were mostly evidence based, but recommendations on BD-associated vascular, neurologic, and gastrointestinal problems were "mainly based on observational studies, retrospective analyses, and clinical experience of the experts" (*Ann. Rheum. Dis.* 2008 Jan. 31 [doi:10.1136/ard.2007.080432]). The guidelines are applicable to many different specialties; the authors hailed from rheumatology, ophthalmology, internal medicine, dermatology, and neurology.

Dr. Yusuf Yazici, who was not on the task force, said in an interview the lack of randomized clinical trials can be explained by the fact that "these are rare manifestations and hard to recruit for, and also vascular and neurologic involvement can be life threatening, and [it's] hard to do a RCT in that situation." Dr. Yazici is the director of the Behçet's Syndrome Evaluation, Treatment and Research Center at the New York University Hospital for Joint Diseases. His father, Dr. Hasan Yazici, was one of the report's authors.

Dr. Yusuf Yazici added there are "no good numbers" to describe the prevalence of the disease in the U.S. BD affects between 1 and 6 people per 100,000, but "these are old numbers; no recent numbers are available," he said.

The nine recommendations are as follows:

► Treat posterior inflammatory eye disease with azathioprine and systemic corticosteroids. The authors cite a study (*N. Engl. J. Med.* 1990;322:281-5) where 2.5 mL/kg per day of azathioprine was efficacious in visual acuity and in halting disease progression.

► Severe eye involvement—greater than a 2-point drop in visual acuity on a 10/10 scale, or retinal disease—calls for a second immunosuppressive. "Cyclosporine A 2-5 mg/kg per day shows its effect rapidly and is, here, usually the treatment of choice," wrote the authors. Influximab and interferon- α are also candidates, though the latter is considered a second choice.

► For BD-associated acute deep vein thrombosis, corticosteroids, azathioprine, cyclophosphamide, or cyclosporine A are recommended. However, "there are no RCTs addressing this issue." The same treatment is recommended for pulmonary and peripheral artery aneurysms.

► Pulmonary embolism is rare, so anticoagulants, antiplatelets, and fibrinolytic agents are not recommended. This is doubly true because of the chance of a coexisting pulmonary arterial aneurysm. Again, however, "controlled trials are needed."

► Immunosuppressants should be the first-line treatment over surgery in case of gastrointestinal ulcers, though no controlled trials exist to support one treatment specifically. "One study reported that azathioprine decreased reoperation rates and

suggested that it should be used as maintenance therapy in patients who require surgery (*Dis. Colon Rectum* 2000;43:692-700)," wrote the authors.

► In most patients, arthritis can be managed with colchicine.

► For parenchymal involvement, "3-7 pulses of intravenous methylprednisone 1 g/day is given during attacks, followed by maintenance oral corticosteroids which is tapered over 2-3 months." However, the authors caution that central nervous sys-

tem (CNS) involvement in BD is mostly based on anecdotal reports.

► Neurotoxic cyclosporine A should not be used in BD patients with CNS involvement unless intraocular inflammation makes it an unavoidable choice.

► Regarding skin involvement, perceived severity should determine treatment. Topical steroids should be first-line treatment in genital and oral ulcers, while acnelike lesions can usually be treated with standard acne vulgaris treatments. In the literature,

azathioprine was effective against resistant skin and mucosa lesions.

"With proper management, remission is frequent in eye disease, skin-mucosa disease, and arthritis," said Dr. Yazici. He added that though CNS disease and thrombotic manifestations pose difficulties, "the disease usually gets better with time. The aim of treatment is to prevent any long-term damage while it is active, since in the long term most patients are doing better and require less medication." ■

Advertisement

Are certain patients at greater risk for rapidly progressing RA?

Joint damage is responsible for much of the disability associated with rheumatoid arthritis (RA).¹ Early diagnosis and effective treatment may play a critical role in preventing functional decline and loss of quality of life—especially in patients with poor prognosis.²

The course of radiologic damage in RA is not completely understood. The amount of damage seen on radiographs of RA patients can vary widely. It remains unclear whether erosions and joint space narrowing are equally important in determining degree of radiologic damage. In addition, there is little detailed information on the rate of progression of radiologic abnormalities from disease onset. Some studies suggest a nonlinear, first-order kinetics model with most of the damage progression occurring in the initial years; other studies suggest a linear, stable rate of progression throughout the course of the disease.³

Despite these questions, there is little doubt about the correlation between radiologic damage and disability in RA.¹ Data from 10 prospective, longitudinal studies indicate significant correlations that become more obvious as disease duration increases.¹ It has been suggested that physical disability in early RA is largely determined by disease activity, while in late RA, joint damage plays a more important role.⁴ In addition, patients at risk for long-term disability are those with seropositive erosive disease and high initial average Health Assessment Questionnaire scores.¹

There is a clear case for identifying and treating RA patients early. Finckh, et al, conducted a meta-analysis of 12 studies to examine the correlation between late therapeutic initiation and joint damage. An average delay in treatment start of 9 months altered disease progression over the long term. However, early initiation of therapy reduced radiologic damage, resulting in a dramatically altered disease progression curve. (See Figure 1.)⁵

Despite the evidence that rapidly progressing RA benefits from early and aggressive treatment, early diagnosis has proven difficult in many patients. In many cases, American College of Rheumatology criteria may not be met in patients who nevertheless will deteriorate rapidly.⁶

There are measurable variables at initial visit that can identify patients at high risk for rapid radiologic progression. (See Table 1.) Of particular interest is arthritis of the large joints, especially the knee.⁷ In a Linn-Rasker, et al, regression analysis of 1009 patients, arthritis of the knee at initial presentation was revealed to be a strong predictor of a more destructive course of disease.⁷ Also compelling is a study by Taylor, et al, that demonstrated a clear relationship between sonographic measurements of synovial thickening and vascularity at baseline to magnitude of radiologic joint damage at Week 54.⁸

These markers may present a means to identify rapidly progressing RA patients early in the course of the disease, rather than risking unsuccessful treatment with less aggressive therapies. Early and more aggressive treatment for appropriately identified patients has the potential to reduce further radiologic joint damage and functional decline.²

Figure 1. Early therapeutic initiation alters RA progression over time⁵




Table 1. Measurable variables at initial visit to identify high-risk patients^{4,6-9}

- Swollen joint count
- Erythrocyte sedimentation rate
- Serum IgM rheumatoid factor
- Arthritis of the large joints, particularly the knee
- Anti-cyclic citrullinated peptide antibodies
- Synovial thickening and vascularity at baseline

References: 1. Scott DL, et al. *Clin Exp Rheumatol.* 2003;21(suppl 31):S20-S27. 2. Quinn MA, et al. *Arthritis Rheum.* 2005;52:27-35. 3. Hulsmans HMJ, et al. *Arthritis Rheum.* 2000;43:1927-1940. 4. Jansen LMA, et al. *Ann Rheum Dis.* 2001;60:924-927. 5. Finckh A, et al. *Arthritis Rheum (Arthritis Care Res).* 2006;55:864-872. 6. Riedemann JP, et al. *Clin Exp Rheumatol.* 2005;23(suppl 39):S69-S76. 7. Linn-Rasker SP, et al. *Ann Rheum Dis.* 2007;66:646-650. 8. Taylor PC, et al. *Arthritis Rheum.* 2004;50:1107-1116. 9. Nishimura K, et al. *Ann Intern Med.* 2007;146:797-808.

centocor
inc

800 Ridgeview Drive
Horsham, PA 19044
USA

©2007 Centocor, Inc. 7/07 CT07079